The FDA's new direction - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The FDA's new direction


Pharmaceutical Technology Europe
Volume 21, Issue 5


Faiz Kermani
As the world's largest pharmaceutical market, the US is frequently targeted by companies for initial drug launches, and this means bending over backwards to convince the FDA that the product is safe and effective. As such, the FDA has a tremendous task on its hands in reviewing the huge amount of regulatory dossiers it receives as submissions, as well as ensuring the safety of products that have already reached the market.

In meeting its regulatory commitments, the FDA can find itself increasingly at odds with pharma companies, which are under pressure to launch as many drugs as possible and to grow their businesses from sales of these products. As the new political administration, under President Barack Obama, has promised a new direction for US healthcare,1 it is inevitable that the FDA will undergo significant change. However, although the agency and pharma have often been at loggerheads, it is the criticism of the general public regarding failings in drug safety that will have a greater impact on the future of the FDA.


The author says...
A reorganization of the regulatory body will have huge implications for the pharmaceutical and biotech industries operating in the US, and will also influence activities in other markets because of the growing interactions between the FDA and its foreign counterparts. In particular, the next few months at the agency will be of great interest to all firms planning drug launches because the regulatory landscape could be about to be revolutionized.

The blame game

There is internal debate within the pharma industry concerning its productivity and innovation in R&D. Year by year, new drug output has steadily declined, despite continuing unmet medical need in a number of important disease areas. The global pharma industry continues to increase its investment in R&D — with an estimated spend of $70 billion (51.7 billion) in 20072 — but the performance of the sector in translating this investment into innovative products remains questionable. Critics of the pharma industry have argued that companies rely too heavily on line extensions and working on new formulations of existing products rather than concentrating their efforts on true innovation in R&D. This has led to companies submitting weaker regulatory dossiers, which in turn has restricted the number of drugs reaching the market.

Some companies have blamed regulatory agencies, such as the FDA, for the decline in new drugs on the market. In 2007, the FDA approved 65 original new drug applications (NDAs), the least since 1999.3 Furthermore, the ratio of NDAs approved to NDAs submitted has dropped from the 76% level of 2006 to less than 60%.4 Many companies believe that the FDA has been excessively bureaucratic, which has slowed the review process.5 One 2008 media report claimed that 15 additional new drugs could have been on the national market if the FDA had been more efficient in conducting its reviews.5 The FDA has a target of meeting 90% of its new drug approval timelines for review, but although full 2008 performance data have not yet been released, the agency has already indicated that it is unlikely to reach this goal.6

Despite these criticisms, the FDA insists it has not changed the way in which it approaches regulatory review. Recently, an agency spokesman stated that the rate of NDA approvals to submissions remained steady at approximately 80% from 1997 through to 20053 — although independent media reports have cited a decline after this period.4


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Improves the quality and number of innovative drugs available to patients.
29%
Restricts innovation and the development of new drugs.
54%
Has no impact on drug development.
4%
Do not know.
13%
Eric Langer Outsourcing Outlook Eric LangerOutsourcing No Longer Just for Cost-Cutting
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerSeeking Alternative Catalyst Solutions
Jill Wechsler Regulatory Watch Jill Wechsler Global Expansion Shapes Drug Oversight
Chris Burgess Statistical Solutions Chris BurgessIs a Sample Size of n=6 a Magic Number?
Sean Milmo European Regulatory WatchSean MilmoRegulating the Environmental Impact of Pharmaceuticals
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Source: Pharmaceutical Technology Europe,
Click here